Just when it seemed like Valeant Pharmaceuticals International Inc.’s luster on Wall Street couldn’t fade further, it has. The company revealed March 15 that sales and earnings for 2016 will be substantially lower than previously forecast in December, even as it has yet to file finalized 2015 financials – at the risk of defaulting on its credit agreements.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?